Valve-in-Valve Hemodynamics of 20-mm Transcatheter Aortic Valves in Small Bioprostheses

Azadani, Ali N.; Jaussaud, Nicolas; Ge, Liang; Chitsaz, Sam; Chuter, Timothy A.M.; Tseng, Elaine E.

doi:10.1016/j.athoracsur.2011.04.009

Cited by 25 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Careful selection of the TAV for ViV needs to be considered to mitigate the risk of paravalvular leakage as well as residual stenosis. 12, 13 When Edwards’ SAPIEN and Medtornic’s CoreValve were implanted in surgical valves with internal diameters less than 20 mm, elevated post-procedural gradients (>20 mmHg) were found in 59% and 20% of patients, respectively 31, 138, 145 . This is thought to be due to the intra-annular nature of the SAPIEN family of valves, whereas CoreValves are supra-annular by design 29 .…”

Section: Introductionmentioning

confidence: 99%

On the Mechanics of Transcatheter Aortic Valve Replacement

et al. 2016

View full text Add to dashboard Cite

Transcatheter aortic valves (TAVs) represent the latest advances in prosthetic heart valve technology. TAVs are truly transformational as they bring the benefit of heart valve replacement to patients that would otherwise not be operated on. Nevertheless, like any new device technology, the high expectations are dampened with growing concerns arising from frequent complications that develop in patients, indicating that the technology is far from being mature. Some of the most common complications that plague current TAV devices include malpositioning, crimp-induced leaflet damage, paravalvular leak, thrombosis, conduction abnormalities and prosthesis-patient mismatch. In this article, we provide an in-depth review of the current state-of-the-art pertaining the mechanics of TAVs while highlighting various studies guiding clinicians, regulatory agencies, and next-generation device designers.

show abstract

Section: Introductionmentioning

confidence: 99%

On the Mechanics of Transcatheter Aortic Valve Replacement

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The long-term fate of this regurgitation is not well known. After the procedure, the patient's symptoms were markedly improved from NYHA class III to class I. Durability and long-term safety of the catheter-based aortic valves need to be clarified in further large-scale clinical trials with long-term follow-ups 9)12)13)…”

Section: Discussionmentioning

confidence: 99%

The First Case of Successful Transcatheter Aortic Valve Implantation Using CoreValve in Korea

Kim

Shin

et al. 2012

Korean Circ J

View full text Add to dashboard Cite

Surgical replacement of the aortic valve is the standard therapy for severe aortic valve stenosis. However, it is generally associated with increased mortality and morbidities in older individuals. Transcatheter aortic valve implantation (TAVI) is a less invasive procedure and has shown similar clinical outcomes as surgical treatment in elderly patients at high risk for conventional surgery. In this report, we describe the first case of TAVI using a CoreValve in Korea. An 84-year-old man with symptomatic severe aortic valve stenosis was successfully treated by transfemoral TAVI. The patient was discharged without any significant complications and remained free of adverse clinical event for a follow-up duration of 6 months.

show abstract

“…The first in‐man Edwards Sapien was performed shortly after through a transapical approach in a 21 mm Perimount aortic valve . Although valve‐in‐valve has become an increasingly appealing strategy, this approach have been shown to be not feasible in 19 mm bio prosthetic valves due to increased gradient after deployment of a transcatheter valve within the transapical valve . There are limited data on percutaneous treatment with the Sapien‐3 device for severe aortic stenosis in patients with 19 mm bioprosthetic valves and here we present the case series study of five patients with severe aortic stenosis caused by degeneration of the 19 mm bioprosthetic aortic valves, successfully treated with transfemoral TAVI using the 20 mm S3 Sapien Commander system.…”

Section: Introductionmentioning

confidence: 98%